News and Trends 16 May 2018 Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […] May 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2018 A New Drug for Atrial Fibrillation Starts Human Testing in Europe Update (14/03/2018): Acesion Pharma has started a Phase I clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands. The trial will test AP30663, a treatment for atrial fibrillation that the company believes has the potential to work better than every option currently available. Originally published on 2/8/2018 The Danish biotech Acesion Pharma […] March 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Mar 2018 Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking over the development of the antibody tralokinumab from AstraZeneca to treat atopic dermatitis after the drug failed multiple Phase III studies for treating asthma. In […] March 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […] February 28, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Startup Scout 26 Jan 2018 This Danish Biotech is Working on Better, Safer Drugs for Cardiac Arrhythmia This week, we’re visiting Acesion Pharma in Copenhagen, a biotech that is developing more effective, safer drugs for atrial fibrillation, the most common form of cardiac arrhythmia. Mission: Since being founded in 2011, Acesion has already caught our attention, being named as one of our top biotechs in Copenhagen. The biotech focuses on the development of […] January 26, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Novartis Takes Genmab’s Leukemia Drug Off the Market Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […] January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water As part of the company’s HelloScience initiative, Novozymes will combine its enzyme and microbial technology with Grundfos’ water pumps to provide clean water and better sanitation. Novozymes aims to improve industrial performance without harming our planet. Earlier this year, the company set up HelloScience, an online platform bringing together experts in a number of fields […] December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […] November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 Welcome to the Blockbuster Club, Genmab! Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of the biotech world by achieving $1B (€850M) in sales of its drug for multiple myeloma, Darzalex. The biotech will now receive milestone payments of $50M (€42M) […] November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Oct 2017 Where to Find the Money to Get Your Biotech Startup Up with the Big Boys What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […] October 24, 2017 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Oct 2017 Meet the Former Banker at the Helm of Denmark’s Healthcare Giant, Novo Holdings Kasim Kutay has ridden the biotech investment wave. First, he helped build Morgan Stanley’s European healthcare group, then did the same at Moelis & Co and now he heads Novo Holdings, the majority shareholder of Danish household biotech names NovoZymes and Novo Nordisk. I asked him about the company’s healthcare investment strategy and his CEO […] October 16, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2017 Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech Jan van de Winkel co-founded Genmab as CSO and then became CEO to develop the antibody company into a fully independent commercial enterprise. Here’s his strategy. Since its foundation in 1999, Genmab has become Europe’s largest biotech and a proud parent of a half billion-euro drug, daratumumab. Co-founding CSO Jan van de Winkel played a […] September 11, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email